ISU Abxis Announces First Patient Dosed in Phase 1 Part 2 of ISU104

  • 관리자
  • 2019-10-10
  • 331
ISU Abxis announced that the first patient has been dosed in a Phase 1 Part 2 clinical trial of ISU104, a monoclonal antibody blocking ErbB3 activation.


The Phase 1 Part 2 clinical study will be conducted at five Korean clinical sites(Asan Medical Center, Seoul National University Hospital, Samsung Medical Center, Kosin University Gospel Hospital, and Kyungpook National University Chilgok Hospital) with 18 patients with recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC; excluding nasopharyngeal cancer).


The Part 2 study is a study that evaluating safety, efficacy, tolerability and pharmacokinetic of ISU104 in mono and combination therapy with cetuximab in patients with recurrent/metastatic HNSCC. The Phase 1 Part 2 study is planned to be done by next year.


ISU Abxis have announced that they presented positive interim results for a Phase 1 Part 1 clinical trial of ISU104 at the European Society of Medical Oncology (ESMO) 2019 Annual Congress.


ISU104 is a monoclonal human antibody targeting ErBb3 that inhibits tumor growth and resistance to the current standard cancer treatments as blocking ligand-dependent ErbB3 activation and inhibiting dimerization of ErbB3 with ErbB1 or ErbB2.